Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
TRIUMPH-1 and TRIUMPH-2 are evaluating the 8 mg and 12 mg doses in adults with obesity with and without type 2 diabetes
If you're exploring GLP-1 treatment options, skip the marketing hype and speak with a licensed healthcare provider who can evaluate whether it's clinically appropriate for you
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
Two therapies may be better, but they double the risk of interaction
We look forward to working with Ascendis to explore the potential of the TransCon technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for cardiometabolic diseases. The closing of this transaction is subject to receipt of applicable regulatory approvals and the parties are seeking to close before the end of 2024
Moreover, this activation seems to feedback resulting in downregulation of CD36 and upregulation of GPR120
US$ 23.19
US$ 29.89
US$ 27.14
US$ 27.63
